Navigation Links
Arpida Reports Interim Results for Six Months to 30 June 2008
Date:8/20/2008

James Bruno to Lead Arpida's North-American Commercial Operations

REINACH, Switzerland, August 20 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the six months ending 30 June 2008.
Highlights 2008 to date

Major pipeline progress:

- Regulatory filings for intravenous iclaprim in cSSSI submitted in

U.S.A. and Europe

- Enrolment in Phase II "intravenous-to-oral" switch trial with oral

iclaprim progresses well

- Enrolment in Phase II HAP/VAP/HCAP trial challenging

- Enrolment in Phase III trial with TLT approaches 50%

- Leadership change to enable Arpida to become a fully integrated

pharmaceutical company

- Raised CHF 19.6 million in a secondary offering in April 2008

- Cash and financial investments of CHF 67.9 million at 30 June 2008

CFO Harry Welten, MBA, commented: "Thanks to continued focus we have managed to keep spending in the first half of 2008 within the guidance given in March this year. Due to the build-up of commercial capabilities, we expect cash spending on operating activities in the second half of 2008 to be around CHF 4.5 million on average per month. Based on our financial position and iclaprim's advanced development status, we feel we are well-placed as we approach 2009, which we expect to be a launch year."

Dr Jürgen Raths, President and CEO, commented: "I am very pleased with the achievements in the year to date, not only in financial terms, but also in terms of development and regulatory progress. Our lead product candidate iclaprim is now under review at the major regulatory authorities on both sides of the Atlantic. We are very much looking forward to hearing from the U.S. authorities in January 2009. After more than 10 years of hard work, Arpida is getting very close to turning what used to be a promising compound into a promising drug, providing physicians with a potent new therapy in the
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The report "Chocolate, Cocoa ... Trade, Prices, Geography Trend and Forecast (2011 - 2016)," ... and geography and studies the major market drivers, restraints, ... Europe, and Asia. , The global chocolate market is ... billion in 2016 at an estimated CAGR of 2.7% ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi Market ... Global Advancements, Forecasts and Analysis (2013 - 2018)", ... with analysis and forecasting of the global revenues. ... and the restrains for this market with the ... Browse 65 market data tables and 69 figures ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... - Trends and Forecasts to 2019", analyzes the ... in order to understand the industry details such ... opportunities across various geographic regions. , Browse 81 ... 202 Slides and in-depth TOC on “1,6-Hexanediol Market ...
(Date:10/18/2014)... The Asia-Pacific Liquid Crystal on Silicon (LCoS) display ... Asia-Pacific with analysis and forecast of revenue. This market ... expected to reach $380.0 million by 2018, at a ... through the TOC of the Asia-Pacific LCoS display market ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... ... HPCwire,s Readers, Choice Award for Best Application of Green Computing. The award was ... ongoing in Portland, Ore. , ... Portland, OR (Vocus) Nov. 17, 2009 --- The U.S. Department of Energy,s ...
... Pharma guarantees to purchase 50,000 KINLYTIC vials over next ... Biosystems Inc. (MBX:TSX), a biotech company focused on virology ... agreement with Riso Pharma that guarantees purchases of not ... years. KINLYTIC (Urokinase) is Microbix, thrombolytic agent for treating ...
... , ROCKVILLE, Md., Nov. 17 Neuralstem, Inc. (NYSE Amex: ... the third quarter ended September 30, 2009. , (Logo: ... of 2009, the Company reported a net loss of $5,096,983, or ... $0.10 per share, for the comparable 2008 period. The increase was ...
Cached Biology Technology:Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 2Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 3Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 4Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 2Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... between 10 and 20 years to develop, providing ... intervention if detected early, which may be possible ... clinical researchers. , Dr Jeremy Humphris and ... Medical Research, analysed medical histories and tumour samples ... patients, operated on between 1994 and 20122. Roughly ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Early detection window when pancreatic cancer is in the family 2
... a long-distance race may do serious harm rather than ... much, according to a cardiologist at UT Southwestern Medical ... too much water during a race could put themselves ... a loss in the body's sodium content that can ...
... announced today the launch of the new GeneChip(R) ... with PreAnalytiX -- a joint venture between QIAGEN ... BD (Becton, Dickinson and Company). The new kits ... use with Affymetrix GeneChip technology and improve gene ...
... Earth history some 251 million years ago was preceded by ... by a delayed recovery that lasted for millions of years. ... a sharp decline in atmospheric oxygen levels was likely a ... very slow recovery. , Earth's land at the time was ...
Cached Biology News:Too much water may be as dangerous as too little during long-distance athletic events 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3Scientists reveal the shape of a protein that helps retroviruses break into cells 2Scientists reveal the shape of a protein that helps retroviruses break into cells 3
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: